ViralClear submited application for Vicromax through FDAs Coronavirus Treatment Acceleration Program for accelerated clinical trials
| | | |

ViralClear submited application for Vicromax through FDAs Coronavirus Treatment Acceleration Program for accelerated clinical trials

On Apr. 21, 2020, BioSig Technologies announced that subsidiary ViralClear Pharmaceuticals, had submitted an application for Vicromax(tm) (merimepodib,…